Vasopressin receptor antagonist

#	Item
1	FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012 Add to Reading List Source URL: www.fda.gov Language: English Medical statistics Lixivaptan Electrolyte disturbances Organochlorides Design of experiments Hyponatremia Clinical trial Vasopressin receptor antagonist Tolvaptan Medicine Health Epidemiology
2	Cardiokine Biopharma, LLC Lixivaptan Briefing Document NDA 203,009 Page 1 of 61 Add to Reading List Source URL: www.fda.gov Language: English Electrolyte disturbances Amides Organochlorides Diuretics Lixivaptan Hyponatremia Syndromes Vasopressin receptor antagonist Hypernatremia Medicine Biology Chemistry
3	The Targeting Acute Congestion with Tolvaptan In Congestive Heart Failure Study TACTICS-HF Felker GM, Adams KF, Cole RT, Patel CB, Egnaczyk G, Mentz RJ, Fiuzat M, and O’Connor CM on behalf of the TACTICS Investigators Add to Reading List Source URL: www.hfsa.org Language: English - Date: 2013-10-11 12:59:07 Health Alcohols Amides Benzazepines Diuretics Tolvaptan Heart failure Placebo Vasopressin receptor antagonist Medicine Chemistry Organochlorides
4	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Add to Reading List Source URL: www.ema.europa.eu Language: English - Date: 2013-08-29 09:13:53 Amines Amides Electrolyte disturbances Diuretics Tolvaptan Hyponatremia Amiodarone Vasopressin receptor antagonist Methadone Chemistry Organic chemistry Organochlorides